What Care Partners Teach Researchers

When people think about research, they often picture clinical trials. A new treatment. A study drug. A chance at something that might change the course of a disease.

But what happens when there is no trial available or if a person diagnosed is unable to participate?

For families affected by frontotemporal degeneration, that is often the reality. FTD is rare. Recruiting enough participants for studies can be difficult. And at any given moment, there may be very few active clinical trials enrolling.

That does not mean research stops. And it certainly does not mean care partners have nothing to contribute.

In fact, care partners teach researchers every day.

Lived experience is data

Care partners see what doctors and researchers often cannot. They notice subtle changes in behavior. They track patterns in sleep, eating, communication, and mobility. They understand how symptoms evolve over months and years.

When care partners participate in the FTD Disorders Registry and enroll in the Registry Research Study, they share this lived experience through structured surveys. These responses are deidentified and combined with others to help researchers identify trends, unmet needs, and real-world impacts of FTD.

That information shapes future studies. It informs what questions researchers ask. It helps define which outcomes truly matter to families.

Defining what “impact” really means

Researchers are trained to measure specific clinical outcomes. Care partners broaden that lens.

They show researchers that impact is not only about a test score or a brain scan. It is about safety in the home. It is about managing impulsivity. It is about communication breakdowns, financial vulnerability, and changes in relationships.

When care partners describe what daily life looks like, they help researchers understand the full impact of FTD. That perspective influences study design, survey development, and the kinds of support services that are prioritized.

Helping research stay grounded

Even when there is no active trial, the Registry community demonstrates something powerful: we are research ready.

Because FTD is rare, every participant matters. Each completed survey strengthens the dataset. Each updated profile helps researchers understand the size and characteristics of the community. Each legally authorized representative who participates on someone’s behalf ensures that people living with advanced FTD are still represented in research.

Numbers have power. They show that the FTD community is engaged, organized, and prepared to move science forward when new opportunities arise.

Shaping the future before a trial begins

Many clinical trials are built on years of observational research. Before a therapy is tested, researchers must understand how a disease progresses, how symptoms vary across subtypes, and which measures are meaningful.

Care partners contribute to that foundation.

By enrolling in the Registry Research Study, keeping information up to date, and completing surveys when invited, care partners help create the evidence base that makes future trials possible.

You do not have to be in a clinical trial to advance research.

Sometimes, the most important lessons researchers learn come from those who are navigating FTD every single day.

If you are a care partner, your experience matters. Your observations matter. Your participation matters.

Together, we are building a research ready community prepared for the moment when the next opportunity arrives.